HeyJaredUnboxing Biotech
Unboxing Biotech is a place where curious minds can find information about biotechnology, pharmaceutical, gene therapy and life sciences companies.
- Indexed videos, last 90 days
- 36
- Latest publication
- Sep 28, 2026
- Audience
- ~564 subscribers
- Earliest in this view
- Jul 3, 2026
Latest videos
Zacks Initiates on Actinium Pharmaceuticals (opens the original)
Read excerpt
Zacks' Senior Life Sciences Analyst John Vandermosten initiates on Actinium Pharmaceuticals with a $4.00 price target. Initiating Coverage – Diversified Nuclear Medicine Portfolio: https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_09152026_ATNM_Vandermosten.pdf I, John Vandermosten, have received compensation from the issuer for this interview and am providing non-investment banking services to this issuer. #ActiniumPharmaceuticals #ATNM #NuclearMedicine #Radiopharmaceuticals #T
Dapibus Benefits for Food Products (opens the original)
Read excerpt
Dyadic Applied Biosolutions' President & Chief Operating Officer, Joe Hazelton, identifies some of Dapibus' advantages in the production of proteins used in food production. #Biotechnology #Biomanufacturing #LifeSciences #AlternativeProteins #PrecisionFermentation $DYAI I, John Vandermosten, have received compensation from the issuer for this interview and am providing non-investment banking services to this issuer. For further disclosures, see Dyadic's recent presentation: https://d2ghdaxqb194v
IFx 2 0 Phase II Study (opens the original)
Read excerpt
Tuhura has a second program for IFx-2.0 in deep seated tumors. If successful, this approach could expand the population that may benefit from IFx. Join CEO Dr. James Bianco as he explains how it's done. $HURA #ImmunoOncology #CancerResearch #LifeSciences I, John Vandermosten, have received compensation from the issuer for this interview and am providing non-investment banking services to this issuer. For further disclosures, see TuHURA's recent presentation: https://ir.tuhurabio.com/_assets/_501
IFx 2 0 New Frontline Standard of Care (opens the original)
Read excerpt
Tuhura is developing IFx-2.0 in Merkel cell carcinoma. If it successfully show synergy with checkpoint inhibitors, it could become the new standard of care. Join CEO Dr. James Bianco as he explains the program's objectives. $HURA #ImmunoOncology #CancerResearch #LifeSciences I, John Vandermosten, have received compensation from the issuer for this interview and am providing non-investment banking services to this issuer. For further disclosures, see TuHURA's recent presentation: https://ir.tuhur
FDA Clearance of TBS 2025 IND (opens the original)
Read excerpt
Earlier today, Tuhura announced that the FDA had cleared its IND for TBS-2025. Join CEO Dr. James Bianco as he explains the rationale behind pursuing VISTA. https://ir.tuhurabio.com/news-events/press-releases/detail/50/tuhura-biosciences-receives-fda-study-may-proceed-notice-and-ind-clearance-for-the-evaluation-of-its-tbs-2025-vista-inhibiting-antibody-in-molecularly-defined-subsets-of-aml-and-other-blood-related-cancers $HURA #ImmunoOncology #CancerResearch #lifesciences I, John Vandermosten, h
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
~564 subscribers
Measured Sep 19, 2026
Source's subscribers, not the number who saw an individual piece.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.